News
ProKidney Corp. (PROK) shares just saw a massive green day. Results from Phase 2 were compelling and the data sharply ...
US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...
The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.
ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...
2h
Zacks.com on MSNPROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy StudyShares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase ...
ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function decline in patients with ...
At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...
ProKidney shares soar on promising Rilparencel mid-stage data for chronic kidney disease. But PROK stock remains a high-risk ...
ProKidney shares jumped 56% in premarket trading after reporting positive topline results from a select population group in a Phase 2 trial evaluating rilparencel in patients with chronic kidney ...
ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday ...
A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results